The SyncroPatch 384 is installed at the FDA for cardiac safety pharmacology studies
Nanion is pleased to announce that a SyncroPatch 384 instrument has been installed at the Food and Drug Administration (…
Nanion is pleased to announce that a SyncroPatch 384 instrument has been installed at the Food and Drug Administration (…
April 17th 2020: Nanion Technologies GmbH, a leading provider of automated patch clamp and cell monitoring systems, anno…
Nanion Technologies, a leading provider of automated electrophysiology systems, today announced the partnership with Ass…
Transporter proteins are gaining increasing interest in academic science and as therapeutic targets. Nanion’s two platfo…
Dr. Costantin has a solid and highly impressive track record in customer relation management, in-depth knowledge of ion…
Nanion Technologies, a leading provider of automated patch clamp platforms, and Axion Biosystems, originator of the firs…
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery t…
Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to hear…
Stem cell derived cardiomyocytes have tremendous potential for cardiac safety testing of drug candidates. By offering an…
Nanion today announces the opening of Nanion Technologies Inc. with headquarters in North Brunswick, NJ, USA. To support…